Download PDF
Thromb Haemost 2003; 90(04): 567-569
DOI: 10.1055/s-0037-1613621
Editorial Focus
Schattauer GmbH

Thromboembolism associated with new anti-cancer treatment strategies in combination with conventional chemotherapy: new drugs, old risks?

Graham J. Caine
1   Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
,
Gregory Y. H. Lip
1   Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received 30 June 2003

Accepted 22 July 2003

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82: 4-6.
    CrossrefPubMedGoogle Scholar
  • 2 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
    CrossrefPubMedGoogle Scholar
  • 3 Relf M. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumour growth factor-β1, platelet-derived endothelial growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-9.
    PubMedGoogle Scholar
  • 4 Yang JC, Haworth L, Steinberg SM. et al. A randomised double-blind placebo-controlled trial of bevacizumab anti-VEGF antibody demonstrating a prolongation time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 2002; 21: 15
    PubMedGoogle Scholar
  • 5 Hurwitz H., Fehrenbacher L., Cartwright T.. et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Program/Proceedings of the American Society of Clinical Oncology 2003 abstract 3646 (in press)
    PubMedGoogle Scholar
  • 6 Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 1997; 14: 1-10.
    CrossrefPubMedGoogle Scholar
  • 7 Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003; 7: 385-97.
    CrossrefPubMedGoogle Scholar
  • 8 Liotta LA, Tryggvason K, Moor WGI. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8.
    CrossrefPubMedGoogle Scholar
  • 9 Itoh T, Tanioka M, Yoshida H. et al. Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res 1998; 58: 1048-51.
    PubMedGoogle Scholar
  • 10 Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma mouse model. Cancer Res 1996; 56: 5279-84.
    PubMedGoogle Scholar
  • 11 Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors: trials and tribulations. Science 2002; 295: 2387-92.
    CrossrefPubMedGoogle Scholar
  • 12 Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomised to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003; 90: 734-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Keunen BC, Rosen L, Smit EF. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-67.
    CrossrefPubMedGoogle Scholar
  • 14 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
    CrossrefPubMedGoogle Scholar
  • 15 Recio FO, Piver MS, Hempling RE. et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157-63.
    CrossrefPubMedGoogle Scholar
  • 16 Caine GJ, Stonelake PS, Lip GYH. et al. The hypercoagulable state of malignancy; pathogenesis and current debate. Neoplasia 2002; 4: 465-73.
    CrossrefPubMedGoogle Scholar
  • 17 Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncology 2002; 3: 27-34.
    CrossrefPubMedGoogle Scholar
  • 18 Hamaad A, Tayebjee MH, Lip GYH. The METHRO trials. Expert Opin Investig Drugs 2003; 12 (05) 865-70.
    CrossrefPubMedGoogle Scholar